2022 04 v.38 937-948
新型冠状病毒疫苗的研究策略及应对奥密克戎等变异株的挑战
基金项目(Foundation):
浙大城市学院科研培育基金资助课题(项目号:J-202106),题目:SARS-CoV-2假病毒感染系统的建立及入侵抑制剂的研究~~
邮箱(Email):
shibojiang@fudan.edu.cn;zhangnr@zucc.edu.cn;
DOI:
10.13242/j.cnki.bingduxuebao.004121
中文作者单位:
浙大城市学院医学院和怀卡托大学联合学院;复旦大学基础医学院;
摘要(Abstract):
自2019年12月新冠肺炎(COVID-19)暴发以来,为有效阻断新型冠状病毒(SARS-CoV-2)的传播,扎实构建人群免疫屏障,全球COVID-19疫苗的研发工作仍在如火如荼的进行着,不同类型的疫苗齐头并进,多种技术路线的疫苗被投入紧急使用。然而,SARS-CoV-2变异株频频出现,现有的疫苗对变异株的保护效力究竟如何是全球普遍关注的话题。本综述从COVID-19疫苗的技术路线、优缺点、实验室研究结果、临床应用和对变异株的保护效力等方面分别阐述DNA疫苗、灭活疫苗、病毒载体疫苗、亚单位疫苗、病毒样颗粒疫苗和mRNA疫苗,期望为应对变异株(特别是奥密克戎株)的COVID-19疫苗的进一步研发奠定科学基础。
关键词(KeyWords):
COVID-19;SARS-CoV-2;奥密克戎株;变异株;疫苗
5,438 | 13 | 64 |
下载次数 | 被引频次 | 阅读次数 |
参考文献
[1] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus:classifying 2019-nCoV and naming it SARS-CoV-2[J/OL]. Nat. Microbiol,2020,5(4):536-544. DOI:10.1038/s41564-020-0695-z.
[2] Weiss S R,Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J/OL]. Microbiol Mol Biol Rev,2005,69(4):635-664. DOI:10.1128/MMBR.69.4.635-664.2005.
[3] Yoshimoto F K. The proteins of severe acute respiratory syndrome coronavirus-2(SARS CoV-2 or n-COV19),the cause of COVID-19[J/OL]. Protein J,2020,39(3):198-216. DOI:10.1007/s10930-020-09901-4.
[4] Tai W,He L,Zhang X,Pu J,Voronin D,Jiang S,Zhou Y,Du L. Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine[J/OL]. Cell Mol Immunol,2020,17(6):613-620. DOI:10.1038/s41423-020-0400-4.
[5] Jeyanathan M,Afkhami S,Smaill F, Miller M S,Lichty B D,Xing Z. Immunological considerations for COVID-19 vaccine strategies[J/OL]. Nat Rev Immunol,2020,20(10):615-632. DOI:10.1038/s41577-020-00434-6.
[6] Leventhal S S,Clancy C,Erasmus J,Feldmann H,Hawman D W. An intramuscular DNA vaccine for SARS-CoV-2 decreases viral lung load but not lung pathology in Syrian hamsters[J/OL]. Microorganisms,2021, 9(5):1040. DOI:10.3390/microorganisms9051040.
[7] Smith T R F,Patel A,Ramos S,Elwood D,Zhu X,Yan J,Gary E N,Walker S N,Schultheis K,Purwar M, Xu Z, Walters J, Bhojnagarwala P, Yang M,Chokkalingam N,Pezzoli P,Parzych E,Reuschel E L,Doan A,Tursi N,Vasquez M,Choi J,Tello-Ruiz E,Maricic I,Bah M A,Wu Y,Amante D,Park D H,Dia Y,Ali A R,Zaidi F I,Generotti A,Kim K Y,Herring T A,Reeder S,Andrade V M,Buttigieg K,Zhao G,Wu J M,Li D,Bao L,Liu J,Deng W,Qin C, Brown A S, Khoshnejad M, Wang N, Chu J,Wrapp D,McLellan J S,Muthumani K,Wang B,Carroll M W,Kim J J,Boyer J,Kulp D W,Humeau L M P F,Weiner D B,Broderick K E. Immunogenicity of a DNA vaccine candidate for COVID-19[J/OL]. Nat Commun,2020,11(1):2601. DOI:10.1038/s41467-020-16505-0.
[8] Conforti A,Marra E,Palombo F,Roscilli G,RavàM,Fumagalli V,Muzi A,Maffei M,Luberto L,Lione L,Salvatori E,Compagnone M,Pinto E,Pavoni E,Bucci F, Vitagliano G, Stoppoloni D, Pacello M L,Cappelletti M,Ferrara F F,D'Acunto E,Chiarini V,Arriga R,Nyska A,Di Lucia P,Marotta D,Bono E,Giustini L,Sala E,Perucchini C,Paterson J,Ryan K A,Challis A R,Matusali G,Colavita F,Caselli G,Criscuolo E,Clementi N,Mancini N,Gro?R,Seidel A,Wettstein L,Münch J,Donnici L,Conti M,De Francesco R, Kuka M, Ciliberto G, Castilletti C,Capobianchi M R,Ippolito G,Guidotti L G,Rovati L,Iannacone M, Aurisicchio L. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective immune responses in animal models[J/OL]. Mol Ther,2022,30(1):311-326. DOI:10.1016/j.ymthe.2021.09.011.
[9] Le T T,Cramer J P,Chen R,Mayhew S. Evolution of the COVID-19 vaccine development landscape[J/OL].Nat Rev Drug Discov,2020,19(10):667-668. DOI:10.1038/d41573-020-00151-8.
[10]Gao Q,Bao L,Mao H,Wang L,Xu K,Yang M,Li Y,Zhu L,Wang N,Lv Z,Gao H,Ge X,Kan B,Hu Y,Liu J,Cai F,Jiang D,Yin Y,Qin C,Li J,Gong X,Lou X,Shi W,Wu D,Zhang H,Zhu L,Deng W,Li Y,Lu J,Li C,Wang X,Yin W,Zhang Y,Qin C.Development of an inactivated vaccine candidate for SARS-CoV-2[J/OL]. Science,2020,369(6499):77-81. DOI:10.1126/science.abc1932.
[11]Wang H,Zhang Y,Huang B,Deng W,Quan Y,Wang W,Xu W,Zhao Y,Li N,Zhang J,Liang H,Bao L,Xu Y,Ding L,Zhou W,Gao H,Liu J,Niu P,Zhao L,Zhen W,Fu H,Yu S,Zhang Z,Xu G,Li C,Lou Z,Xu M,Qin C,Wu G,Gao GF,Tan W,Yang X. Development of an inactivated vaccine candidate,BBIBP-CorV,with potent protection against SARSCoV-2[J/OL]. Cell,2020,182(3):713-721. DOI:10.1016/j.cell.2020.06.008.
[12]Xia S,Zhang Y,Wang Y,Wang H,Yang Y,Gao G F,Tan W,Wu G,Xu M,Lou Z,Huang W,Xu W,Huang B,Wang H,Wang W,Zhang W,Li N,Xie Z,Ding L,You W,Zhao Y,Yang X,Liu Y,Wang Q,Huang L,Yang Y,Xu G,Luo B,Wang W,Liu P,Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J/OL]. Lancet Infect Dis,2021,21(1):39-51.DOI:10.1016/S1473-3099(20)30831-8.
[13]Gilbert S C,Warimwe G M. Rapid development of vaccines against emerging pathogens:The replicationdeficient simian adenovirus platform technology[J/OL].Vaccine,2017,35(35):4461-4464. DOI:10.1016/j.vaccine.2017.04.085.
[14]Kim E,Weisel F J,Balmert S C,Khan M S,Huang S,Erdos G,Kenniston T W,Carey C D,Joachim S M,Conter L J,Weisel N M,Okba N M A,Haagmans B L,Percivalle E,Cassaniti I,Baldanti F,Korkmaz E,Shlomchik M J, Falo L D, Gambotto A. A single subcutaneous or intranasal immunization with adenovirusbased SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice[J/OL]. Eur J Immunol,2021,51(7):1774-1784. DOI:10.1208/s12248-021-00586-w.
[15]Barrett J R,Belij-Rammerstorfer S,Dold C,Ewer K J,Folegatti P M,Gilbride C,Halkerston R,Hill J,Jenkin D,Stockdale L,Verheul M K,Aley P K,Angus B,Bellamy D,Berrie E,Bibi S,Bittaye M,Carroll M W,Cavell B,Clutterbuck E A,Edwards N,Flaxman A,Fuskova M,Gorringe A,Hallis B,Kerridge S,Lawrie A M,Linder A,Liu X,Madhavan M,Makinson R,Mellors J, Minassian A, Moore M, Mujadidi Y,Plested E,Poulton I,Ramasamy M N,Robinson H,Rollier C S,Song R,Snape M D,Tarrant R,Taylor S,Thomas K M,Voysey M,Watson M E E,Wright D,Douglas A D,Green C M,Hill A V S,Lambe T,Gilbert S,Pollard A J;Oxford COVID Vaccine Trial Group. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses[J/OL]. Nat Med,2021,27(2):279-288. DOI:10.1038/s41591-020-01179-4.
[16]King R G,Silva-Sanchez A,Peel J N,Botta D,Dickson A M,Pinto A K,Meza-Perez S,Allie S R,Schultz M D,Liu M,Bradley JE,Qiu S,Yang G,Zhou F,Zumaquero E,Simpler T S,Mousseau B,Killian J T,Dean B,Shang Q,Tipper J L,Risley C A,Harrod K S,Feng T,Lee Y,Shiberu B,Krishnan V,Peguillet I,Zhang J,Green T J,Randall T D,Suschak J J,Georges B,Brien J D,Lund F E,Roberts M S. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARSCoV-2 and fully protects mice from lethal challenge[J/OL]. Vaccines(Basel), 2021, 9(8):881. DOI:10.3390/vaccines9080881.
[17]Hassan A O, Feldmann F, Zhao H, Curiel D T,Okumura A,Tang-Huau T L,Case J B,Meade-White K,Callison J,Lovaglio J,Hanley P W,Scott D P,Fremont D H,Feldmann H,Diamond M S. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques[J/OL]. Cell Rep Med,2021,2(4):100230.DOI:10.1101/2021.01.26.428251.
[18]Menni C,Klaser K,May A,Polidori L,Capdevila J,Louca P,Sudre C H,Nguyen L H,Drew D A,Merino J,Hu C,Selvachandran S,Antonelli M,Murray B,Canas L S,Molteni E,Graham M S,Modat M,Joshi A D,Mangino M,Hammers A,Goodman A L,Chan A T,Wolf J,Steves C J,Valdes A M,Ourselin S,Spector T D. Vaccine side-effects and SARS-CoV-2infection after vaccination in users of the COVID Symptom Study app in the UK:a prospective observational study[J/OL]. Lancet Infect Dis,2021,21(7):939-949. DOI:10.1016/S1473-3099(21)00224-3.
[19]Warner B M,Santry L A,Leacy A,Chan M,Pham P H, Vendramelli R, Pei Y, Tailor N, Valcourt E,Leung A,He S,Griffin B D,Audet J,Willman M,Tierney K,Albietz A,Frost K L,Yates J G E,Mould R C,Chan L,Mehrani Y,Knapp J P,Minott J A,Banadyga L,Safronetz D,Wood H,Booth S,Major P P,Bridle B W,Susta L,Kobasa D,Wootton S K.Intranasal vaccination with a Newcastle disease virusvectored vaccine protects hamsters from SARS-CoV-2infection and disease[J/OL]. iScience,2021,24(11):103219. DOI:10.1016/j.isci.2021.103219.
[20]Li H,Zhang Y,Li D,Deng Y Q,Xu H,Zhao C,Liu J,Wen D,Zhao J,Li Y,Wu Y,Liu S,Liu J,Hao J,Yuan F, Duo S, Qin C F, Zheng A. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein[J/OL].Signal Transduct Target Ther,2021,6(1):1-12. DOI:10.1038/s41392-021-00797-9.
[21]Malherbe D C,Kurup D,Wirblich C,Ronk A J,Mire C,Kuzmina N,Shaik N,Periasamy S,Hyde M A,Williams J M,Shi P Y,Schnell M J,Bukreyev A. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19[J/OL]. NPJ Vaccines, 2021, 6(1):91. DOI:10.1038/s41541-021-00352-1.
[22]Loes A N,Gentles L E,Greaney A J,Crawford K H D,Bloom J D. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice[J/OL]. Viruses,2020,12(9):987. DOI:10.3390/v12090987.
[23]Koonpaew S, Kaewborisuth C, Srisutthisamphan K,Wanitchang A,Thaweerattanasinp T,Saenboonrueng J,Poonsuk S,Jengarn J,Viriyakitkosol R,Kramyu J,Jongkaewwattana A. A single-cycle influenza A virusbased SARS-CoV-2 vaccine elicits potent immune responses in a mouse model[J/OL]. Vaccines,2021,9(8):850. DOI:10.3390/vaccines9080850.
[24]Liu X,Luongo C,Matsuoka Y,Park H S,Santos C,Yang L,Moore I N,Afroz S,Johnson R F,Lafont B A P,Martens C,Best S M,Munster V J,HollyJ,Yewdell J W,Le Nou?n C,Munir S,Buchholz U J. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters[J/OL]. Proc Natl Acad Sci U S A,2021,118(50):e2109744118. DOI:10.1073/pnas.2109744118.
[25]Ohtsuka J,Imai M,Fukumura M,Maeda M,Eguchi A,Ono R,Maemura T,Ito M,Yamayoshi S,Kataoka Y,Kawaoka Y,Nosaka T. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2[J/OL]. iScience,2021,24(12):103379. DOI:10.1016/j.isci.2021.103379.
[26]Keech C,Albert G,Cho I,Robertson A,Reed P,Neal S,Plested J S,Zhu M,Cloney-Clark S,Zhou H,Smith G,Patel N,Frieman M B,Haupt R E,Logue J,McGrath M,Weston S,Piedra P A,Desai C,Callahan K,Lewis M,Price-Abbott P,Formica N,Shinde V,Fries L,Lickliter J D,Griffin P,Wilkinson B,Glenn G M. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J/OL]. N Engl J Med,2020, 383(24):2320-2332. DOI:10.1056/NEJMoa2026920.
[27]Salvatori G, Luberto L, Maffei M, Aurisicchio L,Roscilli G,Palombo F,Marra E. SARS-CoV-2 SPIKE PROTEIN:an optimal immunological target for vaccines[J/OL]. J Transl Med,2020,18(1):222.DOI:10.1186/s12967-020-02392-y.
[28]Guebre-Xabier M, Patel N, Tian J H, Zhou B,Maciejewski S,Lam K,Portnoff A D,Massare M J,Frieman M B,Piedra P A,Ellingsworth L,Glenn G,Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2challenge[J/OL]. Vaccine,2020,38(50):7892-7896.DOI:10.1016/j.vaccine.2020.10.064.
[29]Richmond P,Hatchuel L,Dong M,Ma B,Hu B,Smolenov I, Li P, Liang P, Han H H, Liang J,Clemens R. Safety and immunogenicity of S-Trimer(SCB-2019),a protein subunit vaccine candidate for COVID-19 in healthy adults:a phase 1,randomised,double-blind, placebo-controlled trial[J/OL]. The Lancet,2021,397(10275):682-694. DOI:10.1016/S0140-6736(21)00241-5.
[30]Xu R,Shi M,Li J,Song P,Li N. Construction of SARS-CoV-2 virus-like particles by mammalian expression system[J/OL]. Front Bioeng Biotechnol,2020,8:862. DOI:10.3389/fbioe.2020.00862.
[31]Mohsen M O,Balke I,Zinkhan S,Zeltina V,Liu X,Chang X,Krenger P S,Plattner K,Gharailoo Z,Vogt A S,Augusto G,Zwicker M,Roongta S,Rothen D A,Josi R,Costa J J D,Sobczak J M,Nonic A,Brand L A,Nuss K,Martina B,Speiser D E,Kündig T,Jennings G T,Walton S M,Vogel M,Zeltins A,Bachmann M F. A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2[J/OL]. Allergy,2022,77(1):243-257. DOI:10.1111/all.15080.
[32]Hennrich A A,Sawatsky B,Santos-Mandujano R,Banda D H,Oberhuber M,Schopf A,Pfaffinger V,Wittwer K,Riedel C,Pfaller C K,Conzelmann K K.Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19:Protection of mice after a single immunization[J/OL]. PLoS Pathog,2021, 17(4):e1009064. DOI:10.1371/journal.ppat.1009064.
[33]Xia J,Lu G,Lu J,Z J,Feng L,Wang B,Yu H,Xu Y,Lin J. Towards an effective mRNA vaccine against2019-nCoV:demonstration of virus-like particles expressed from a modified mRNA cocktail[J/OL].ChinaXiv,2020. DOI:10.12074/202002.00070.
[34]World Health Organization. Tracking SARS-CoV-2variants[EB/OL].[2021-12-14]. http://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[35]Aleem A,A B A S,Slenker A K. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus(COVID-19)[B]. In:StatPearls[Internet]. Treasure Island(FL):StatPearls Publishing,2022.
[36]Zhang X,Wu S,Wu B,Yang Q,Chen A,Li Y,Zhang Y,Pan T,Zhang H,He X. SARS-CoV-2Omicron strain exhibits potent capabilities for immune evasion and viral entrance[J/OL]. Signal Transduct Target Ther,2021,6(1):1-3. DOI:10.1038/s41392-021-00852-5.
[37]Puranik A,Lenehan P J,Silvert E,Niesen M J M,Corchado-Garcia J,O'Horo J C,Virk A,Swift M D,Halamka J, Badley A D, Venkatakrishnan A J,Soundararajan V. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence[J/OL]. medRxiv,2021.DOI:10.1101/2021.08.06.21261707.
[38]Heath P T, Galiza E P, Baxter D N, Boffito M,Browne D, Burns F, Chadwick D R, Clark R,Cosgrove C,Galloway J,Goodman A L,Heer A,Higham A,Iyengar S,Jamal A,Jeanes C,Kalra P A,Kyriakidou C,McAuley D F,Meyrick A,Minassian A M, Minton J, Moore P, Munsoor I, Nicholls H,Osanlou O,Packham J,Pretswell C H,San Francisco Ramos A,Saralaya D,Sheridan R P,Smith R,Soiza R L,Swift P A,Thomson E C,Turner J,Viljoen M E,Albert G,Cho I,Dubovsky F,Glenn G,Rivers J,Robertson A,Smith K,Toback S;2019nCoV-302GroupStudy. Safety and efficacy of NVX-CoV2373COVID-19 vaccine[J/OL]. N Engl J Med,2021,385(13):1172-1183. DOI:10.1056/NEJMoa2107659.
[39]Brinkkemper M, Brouwer P J M, Maisonnasse P,Grobben M,Caniels T G,Poniman M,Burger J A,Bontjer I,Oomen M,Bouhuijs J H,van der Linden C A,Villaudy J,van der Velden Y U,Sliepen K,van Gils M J,Le Grand R,Sanders R W. A third SARSCoV-2 spike vaccination improves neutralization of variants-of-concern[J/OL]. NPJ Vaccines,2021,6(1):146. DOI:10.1038/s41541-021-00411-7.
[40]Emary K R W,Golubchik T,Aley P K, Ariani C V,Angus B,Bibi S,Blane B,Bonsall D,Cicconi P,Charlton S,Clutterbuck E A,Collins A M,Cox T,Darton T C,Dold C,Douglas A D,Duncan C J A,Ewer K J,Flaxman A L,Faust S N,Ferreira D M,Feng S,Finn A,Folegatti P M,Fuskova M,Galiza E,Goodman A L,Green C M,Green C A,Greenland M,Hallis B,Heath P T,Hay J,Hill H C,Jenkin D,Kerridge S,Lazarus R,Libri V,Lillie P J,Ludden C,Marchevsky N G,Minassian A M,McGregor A C,Mujadidi Y F,Phillips D J,Plested E,Pollock K M,Robinson H, Smith A, Song R, Snape M D,Sutherland R K,Thomson E C,Toshner M,Turner D P J,Vekemans J,Villafana T L,Williams C J,Hill A V S,Lambe T,Gilbert S C,Voysey M,Ramasamy M N,Pollard A J;COVID-19 Genomics UK consortium;AMPHEUS Project;Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 variant of concern 202012/01(B. 1.1. 7):an exploratory analysis of a randomised controlled trial[J/OL]. Lancet,2021,397(10282):1351-1362. DOI:10.1016/S0140-6736(21)00628-0.
[41]Kustin T,Harel N,Finkel U,Perchik S,Harari S,Tahor M,Caspi I,Levy R,Leshchinsky M,Ken Dror S,Bergerzon G,Gadban H,Gadban F,Eliassian E,Shimron O,Saleh L,Ben-Zvi H,Keren Taraday E,Amichay D,Ben-Dor A,Sagas D,Strauss M,Shemer Avni Y,Huppert A,Kepten E,Balicer R D,Netzer D,Ben-Shachar S,Stern A. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals[J/OL].Nat Med,2021,27(8):1379-1384. DOI:10.1038/s41591-021-01413-7.
[42]Gómez C E, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19[J/OL].Vaccines(Basel),2021,9(3):243. DOI:10.3390/vaccines9030243.
[43]Starr T N, Greaney A J, Hilton S K, Ellis D,Crawford K H D,Dingens A S,Navarro M J,Bowen J E,Tortorici M A,Walls A C,King N P,Veesler D,Bloom J D. Deep mutational scanning of SARS-CoV-2receptor binding domain reveals constraints on folding and ACE2 binding[J/OL]. Cell,2020,182(5):1295-1310. DOI:10.1016/j.cell.2020.08.012.
[44]Jangra S, Ye C, Rathnasinghe R, Stadlbauer D,Krammer F,Simon V,Martinez-Sobrido L,GarciaSastre A,Schotsaert M. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and postvaccination sera[J/OL]. medRxiv,2021.DOI:10.1101/2021.01.26.21250543.
[45]Ranzani O T,Hitchings M D T,Dorion M,D'Agostini T L,de Paula R C,de Paula O F P,Villela E F M,Torres M S S,de Oliveira S B,Schulz W,Almiron M,Said R,de Oliveira R D,Vieira da Silva P,de Araújo W N,Gorinchteyn J C,Andrews J R,Cummings D A T,Ko A I,Croda J. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil:test negative case-control study[J/OL]. BMJ,2021,374:n2015. DOI:10.1136/bmj.n2091.
[46]Chung H,He S,Nasreen S,Sundaram M E,Buchan S A,Wilson S E,Chen B,Calzavara A,Fell D B,Austin P C,Wilson K,Schwartz K L,Brown K A,Gubbay J B,Basta N E,Mahmud S M,Righolt C H,Svenson L W,MacDonald S E,Janjua N Z,Tadrous M, Kwong J C; Canadian Immunization Research Network(CIRN)Provincial Collaborative Network(PCN)Investigators. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario,Canada:test negative design study[J/OL].BMJ,2021,374:n1943. DOI:10.1136/bmj.n1943.
[47]Sapkal G N,Yadav P D,Sahay R R,Deshpande G,Gupta N,Nyayanit D A,Patil D Y,Shete A M,Kumar S, Abraham P, Panda S, Bhargava B.Neutralization of Delta variant with sera of Covishield?vaccinees and COVID-19-recovered vaccinated individuals[J/OL]. J Travel Me,2021,28(7):taab119.DOI:10.1093/jtm/taab119.
[48]Jara A, Undurraga E A, González C, Paredes F,Fontecilla T,Jara G,Pizarro A,Acevedo J,Leo K,Leon F, Sans C, Leighton P, Suárez P, GarcíaEscorza H, Araos R. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile[J/OL]. N Engl J Med,2021, 385(10):875-884. DOI:10.1056/NEJMoa2107715.
[49]叶青.国产疫苗对德尔塔变异株有效吗?钟南山这样说[N].科技日报,2021. DOI:10.28502/n. cnki.nkjrb.2021.003499.
[50]Richmond P C, Hatchuel L, Pacciarini F, Hu B,Smolenov I, Li P, Liang P, Han H H, Liang J,Clemens R. Persistence of the immune responses and cross-neutralizing activity with variants of concern following 2 doses of adjuvanted SCB-2019 coronavirus disease 2019 vaccine[J/OL]. J Infect Dis,2021,224(10):1699-1706. DOI:10.1093/infdis/jiab447.
[51]Ambrosino D,Han H H,Hu B,Liang J,Clemens R,Johnson M,Siber G,Goldblatt D. Immunogenicity of SCB-2019 coronavirus disease 2019 vaccine compared with 4 approved vaccines[J/OL]. J Infect Dis,2022,225(2):327-331. DOI:10.1093/infdis/jiab574.
[52]Chen J,Wang R,Gilby N B,Wei G W. Omicron(B.1.1. 529):Infectivity, breakthroughvaccine, and antibody resistance[J/OL]. J Chem Inf Model,2022,62(2):412-422. DOI:10.1021/acs.jcim.1c01451.
[53]Cele S,Jackson L,Khan K,Khoury D,Moyo-Gwete T,Tegally H,Scheepers C,Amoako D,Karim F,Bernstein M,Lustig G,Archary D,Smith M,Ganga Y,Jule Z,Reedoy K,San J E,Hwa S H,Giandhari J,Blackburn J M,Gosnell B I,Karim S A,Hanekom W,NGS-SA,Team C K,von Gottberg A,Bhiman J,Lessells R J,Moosa M Y S,Davenport M,de Oliveira T,Moore P L,Sigal A. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2elicited neutralization and requires ACE2 for infection[J/OL].medRxiv, 2021.DOI:10.1101/2021.12.08.21267417.
[54]Wang Y,Zhang L,Li Q,Liang Z,Li T,Liu S,Cui Q,Nie J,Wu Q,Qu X,Huang W. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron[J/OL]. Emerg Microbes Infect,2022,11(1):1-5. DOI:10.1080/22221751.2021.2017757.
[55]Su S,Wang Q,Jiang S. Facing the challenge of viral mutations in the age of pandemic:Developing highly potent,broad-spectrum,and safe COVID-19 vaccines and therapeutics[J/OL]. Clin Transl Med,2021,11(1):e284. DOI:10.1002/ctm2.284.
[56]王李珏,刘泽众,姜世勃.新冠疫苗的有效性、安全性和广谱性的商榷[J/OL].中国科学基金,2020,34(05):588-593. DOI:10.16262/j. cnki. 1000-8217.20200914.001.
[57]Su S, Du L, Jiang S. Learning from the past:development of safe and effective COVID-19 vaccines[J/OL]. Nat Rev Microbiol,2021,19(3):211-219. DOI:10.1038/s41579-020-00462-y.
[58]Rosati M, Agarwal M, Hu X, Devasundaram S,Stellas D,Chowdhury B,Bear J,Burns R,Donohue D,Pessaint L,Andersen H,Lewis M G,Terpos E,Dimopoulos M A,Wlodawer A,Mullins J I,Venzon D J,Pavlakis G N,Felber B K. Control of SARS-CoV-2infection after Spike DNA or Spike DNA+Protein coimmunization in rhesus macaques[J/OL]. bioRxiv,2021. DOI:10.1371/journal.ppat.1009701.
[59]Rice A, Verma M, Shin A, Zakin L, Sieling P,Tanaka S,Balint J,Dinkins K,Adisetiyo H,Morimoto B,Higashide W,Anders Olson C,Mody S,Spilman P,Gabitzsch E,Safrit J T,Rabizadeh S,Niazi K,Soon-Shiong P. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice[J/OL]. Sci Rep,2021,11(1):1-15. DOI:10.1038/s41598-021-94364-5.
[60]Jangra S,Landers J J,Rathnasinghe R,O'Konek J J,Janczak K W,Cascalho M,Kennedy A A,Tai A W,Baker J R,Schotsaert M,Wong P T. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine[J/OL]. Front Immunol, 2021, 12:729189.DOI:10.3389/fimmu.2021.729189.
[61]Liu Y,Dai L,Feng X,Gao R,Zhang N,Wang B,Han J,Zou Q,Guo X,Zhu H,Liu J,Qin C,Zhang Y,Bao L,Li M. Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA[J/OL]. Mol Biomed,2021,2(1):1-13. DOI:10.1186/s43556-021-00054-z.
[2] Weiss S R,Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus[J/OL]. Microbiol Mol Biol Rev,2005,69(4):635-664. DOI:10.1128/MMBR.69.4.635-664.2005.
[3] Yoshimoto F K. The proteins of severe acute respiratory syndrome coronavirus-2(SARS CoV-2 or n-COV19),the cause of COVID-19[J/OL]. Protein J,2020,39(3):198-216. DOI:10.1007/s10930-020-09901-4.
[4] Tai W,He L,Zhang X,Pu J,Voronin D,Jiang S,Zhou Y,Du L. Characterization of the receptor-binding domain(RBD)of 2019 novel coronavirus:implication for development of RBD protein as a viral attachment inhibitor and vaccine[J/OL]. Cell Mol Immunol,2020,17(6):613-620. DOI:10.1038/s41423-020-0400-4.
[5] Jeyanathan M,Afkhami S,Smaill F, Miller M S,Lichty B D,Xing Z. Immunological considerations for COVID-19 vaccine strategies[J/OL]. Nat Rev Immunol,2020,20(10):615-632. DOI:10.1038/s41577-020-00434-6.
[6] Leventhal S S,Clancy C,Erasmus J,Feldmann H,Hawman D W. An intramuscular DNA vaccine for SARS-CoV-2 decreases viral lung load but not lung pathology in Syrian hamsters[J/OL]. Microorganisms,2021, 9(5):1040. DOI:10.3390/microorganisms9051040.
[7] Smith T R F,Patel A,Ramos S,Elwood D,Zhu X,Yan J,Gary E N,Walker S N,Schultheis K,Purwar M, Xu Z, Walters J, Bhojnagarwala P, Yang M,Chokkalingam N,Pezzoli P,Parzych E,Reuschel E L,Doan A,Tursi N,Vasquez M,Choi J,Tello-Ruiz E,Maricic I,Bah M A,Wu Y,Amante D,Park D H,Dia Y,Ali A R,Zaidi F I,Generotti A,Kim K Y,Herring T A,Reeder S,Andrade V M,Buttigieg K,Zhao G,Wu J M,Li D,Bao L,Liu J,Deng W,Qin C, Brown A S, Khoshnejad M, Wang N, Chu J,Wrapp D,McLellan J S,Muthumani K,Wang B,Carroll M W,Kim J J,Boyer J,Kulp D W,Humeau L M P F,Weiner D B,Broderick K E. Immunogenicity of a DNA vaccine candidate for COVID-19[J/OL]. Nat Commun,2020,11(1):2601. DOI:10.1038/s41467-020-16505-0.
[8] Conforti A,Marra E,Palombo F,Roscilli G,RavàM,Fumagalli V,Muzi A,Maffei M,Luberto L,Lione L,Salvatori E,Compagnone M,Pinto E,Pavoni E,Bucci F, Vitagliano G, Stoppoloni D, Pacello M L,Cappelletti M,Ferrara F F,D'Acunto E,Chiarini V,Arriga R,Nyska A,Di Lucia P,Marotta D,Bono E,Giustini L,Sala E,Perucchini C,Paterson J,Ryan K A,Challis A R,Matusali G,Colavita F,Caselli G,Criscuolo E,Clementi N,Mancini N,Gro?R,Seidel A,Wettstein L,Münch J,Donnici L,Conti M,De Francesco R, Kuka M, Ciliberto G, Castilletti C,Capobianchi M R,Ippolito G,Guidotti L G,Rovati L,Iannacone M, Aurisicchio L. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective immune responses in animal models[J/OL]. Mol Ther,2022,30(1):311-326. DOI:10.1016/j.ymthe.2021.09.011.
[9] Le T T,Cramer J P,Chen R,Mayhew S. Evolution of the COVID-19 vaccine development landscape[J/OL].Nat Rev Drug Discov,2020,19(10):667-668. DOI:10.1038/d41573-020-00151-8.
[10]Gao Q,Bao L,Mao H,Wang L,Xu K,Yang M,Li Y,Zhu L,Wang N,Lv Z,Gao H,Ge X,Kan B,Hu Y,Liu J,Cai F,Jiang D,Yin Y,Qin C,Li J,Gong X,Lou X,Shi W,Wu D,Zhang H,Zhu L,Deng W,Li Y,Lu J,Li C,Wang X,Yin W,Zhang Y,Qin C.Development of an inactivated vaccine candidate for SARS-CoV-2[J/OL]. Science,2020,369(6499):77-81. DOI:10.1126/science.abc1932.
[11]Wang H,Zhang Y,Huang B,Deng W,Quan Y,Wang W,Xu W,Zhao Y,Li N,Zhang J,Liang H,Bao L,Xu Y,Ding L,Zhou W,Gao H,Liu J,Niu P,Zhao L,Zhen W,Fu H,Yu S,Zhang Z,Xu G,Li C,Lou Z,Xu M,Qin C,Wu G,Gao GF,Tan W,Yang X. Development of an inactivated vaccine candidate,BBIBP-CorV,with potent protection against SARSCoV-2[J/OL]. Cell,2020,182(3):713-721. DOI:10.1016/j.cell.2020.06.008.
[12]Xia S,Zhang Y,Wang Y,Wang H,Yang Y,Gao G F,Tan W,Wu G,Xu M,Lou Z,Huang W,Xu W,Huang B,Wang H,Wang W,Zhang W,Li N,Xie Z,Ding L,You W,Zhao Y,Yang X,Liu Y,Wang Q,Huang L,Yang Y,Xu G,Luo B,Wang W,Liu P,Guo W, Yang X. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J/OL]. Lancet Infect Dis,2021,21(1):39-51.DOI:10.1016/S1473-3099(20)30831-8.
[13]Gilbert S C,Warimwe G M. Rapid development of vaccines against emerging pathogens:The replicationdeficient simian adenovirus platform technology[J/OL].Vaccine,2017,35(35):4461-4464. DOI:10.1016/j.vaccine.2017.04.085.
[14]Kim E,Weisel F J,Balmert S C,Khan M S,Huang S,Erdos G,Kenniston T W,Carey C D,Joachim S M,Conter L J,Weisel N M,Okba N M A,Haagmans B L,Percivalle E,Cassaniti I,Baldanti F,Korkmaz E,Shlomchik M J, Falo L D, Gambotto A. A single subcutaneous or intranasal immunization with adenovirusbased SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice[J/OL]. Eur J Immunol,2021,51(7):1774-1784. DOI:10.1208/s12248-021-00586-w.
[15]Barrett J R,Belij-Rammerstorfer S,Dold C,Ewer K J,Folegatti P M,Gilbride C,Halkerston R,Hill J,Jenkin D,Stockdale L,Verheul M K,Aley P K,Angus B,Bellamy D,Berrie E,Bibi S,Bittaye M,Carroll M W,Cavell B,Clutterbuck E A,Edwards N,Flaxman A,Fuskova M,Gorringe A,Hallis B,Kerridge S,Lawrie A M,Linder A,Liu X,Madhavan M,Makinson R,Mellors J, Minassian A, Moore M, Mujadidi Y,Plested E,Poulton I,Ramasamy M N,Robinson H,Rollier C S,Song R,Snape M D,Tarrant R,Taylor S,Thomas K M,Voysey M,Watson M E E,Wright D,Douglas A D,Green C M,Hill A V S,Lambe T,Gilbert S,Pollard A J;Oxford COVID Vaccine Trial Group. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses[J/OL]. Nat Med,2021,27(2):279-288. DOI:10.1038/s41591-020-01179-4.
[16]King R G,Silva-Sanchez A,Peel J N,Botta D,Dickson A M,Pinto A K,Meza-Perez S,Allie S R,Schultz M D,Liu M,Bradley JE,Qiu S,Yang G,Zhou F,Zumaquero E,Simpler T S,Mousseau B,Killian J T,Dean B,Shang Q,Tipper J L,Risley C A,Harrod K S,Feng T,Lee Y,Shiberu B,Krishnan V,Peguillet I,Zhang J,Green T J,Randall T D,Suschak J J,Georges B,Brien J D,Lund F E,Roberts M S. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARSCoV-2 and fully protects mice from lethal challenge[J/OL]. Vaccines(Basel), 2021, 9(8):881. DOI:10.3390/vaccines9080881.
[17]Hassan A O, Feldmann F, Zhao H, Curiel D T,Okumura A,Tang-Huau T L,Case J B,Meade-White K,Callison J,Lovaglio J,Hanley P W,Scott D P,Fremont D H,Feldmann H,Diamond M S. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques[J/OL]. Cell Rep Med,2021,2(4):100230.DOI:10.1101/2021.01.26.428251.
[18]Menni C,Klaser K,May A,Polidori L,Capdevila J,Louca P,Sudre C H,Nguyen L H,Drew D A,Merino J,Hu C,Selvachandran S,Antonelli M,Murray B,Canas L S,Molteni E,Graham M S,Modat M,Joshi A D,Mangino M,Hammers A,Goodman A L,Chan A T,Wolf J,Steves C J,Valdes A M,Ourselin S,Spector T D. Vaccine side-effects and SARS-CoV-2infection after vaccination in users of the COVID Symptom Study app in the UK:a prospective observational study[J/OL]. Lancet Infect Dis,2021,21(7):939-949. DOI:10.1016/S1473-3099(21)00224-3.
[19]Warner B M,Santry L A,Leacy A,Chan M,Pham P H, Vendramelli R, Pei Y, Tailor N, Valcourt E,Leung A,He S,Griffin B D,Audet J,Willman M,Tierney K,Albietz A,Frost K L,Yates J G E,Mould R C,Chan L,Mehrani Y,Knapp J P,Minott J A,Banadyga L,Safronetz D,Wood H,Booth S,Major P P,Bridle B W,Susta L,Kobasa D,Wootton S K.Intranasal vaccination with a Newcastle disease virusvectored vaccine protects hamsters from SARS-CoV-2infection and disease[J/OL]. iScience,2021,24(11):103219. DOI:10.1016/j.isci.2021.103219.
[20]Li H,Zhang Y,Li D,Deng Y Q,Xu H,Zhao C,Liu J,Wen D,Zhao J,Li Y,Wu Y,Liu S,Liu J,Hao J,Yuan F, Duo S, Qin C F, Zheng A. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein[J/OL].Signal Transduct Target Ther,2021,6(1):1-12. DOI:10.1038/s41392-021-00797-9.
[21]Malherbe D C,Kurup D,Wirblich C,Ronk A J,Mire C,Kuzmina N,Shaik N,Periasamy S,Hyde M A,Williams J M,Shi P Y,Schnell M J,Bukreyev A. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19[J/OL]. NPJ Vaccines, 2021, 6(1):91. DOI:10.1038/s41541-021-00352-1.
[22]Loes A N,Gentles L E,Greaney A J,Crawford K H D,Bloom J D. Attenuated influenza virions expressing the SARS-CoV-2 receptor-binding domain induce neutralizing antibodies in mice[J/OL]. Viruses,2020,12(9):987. DOI:10.3390/v12090987.
[23]Koonpaew S, Kaewborisuth C, Srisutthisamphan K,Wanitchang A,Thaweerattanasinp T,Saenboonrueng J,Poonsuk S,Jengarn J,Viriyakitkosol R,Kramyu J,Jongkaewwattana A. A single-cycle influenza A virusbased SARS-CoV-2 vaccine elicits potent immune responses in a mouse model[J/OL]. Vaccines,2021,9(8):850. DOI:10.3390/vaccines9080850.
[24]Liu X,Luongo C,Matsuoka Y,Park H S,Santos C,Yang L,Moore I N,Afroz S,Johnson R F,Lafont B A P,Martens C,Best S M,Munster V J,HollyJ,Yewdell J W,Le Nou?n C,Munir S,Buchholz U J. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters[J/OL]. Proc Natl Acad Sci U S A,2021,118(50):e2109744118. DOI:10.1073/pnas.2109744118.
[25]Ohtsuka J,Imai M,Fukumura M,Maeda M,Eguchi A,Ono R,Maemura T,Ito M,Yamayoshi S,Kataoka Y,Kawaoka Y,Nosaka T. Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2[J/OL]. iScience,2021,24(12):103379. DOI:10.1016/j.isci.2021.103379.
[26]Keech C,Albert G,Cho I,Robertson A,Reed P,Neal S,Plested J S,Zhu M,Cloney-Clark S,Zhou H,Smith G,Patel N,Frieman M B,Haupt R E,Logue J,McGrath M,Weston S,Piedra P A,Desai C,Callahan K,Lewis M,Price-Abbott P,Formica N,Shinde V,Fries L,Lickliter J D,Griffin P,Wilkinson B,Glenn G M. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J/OL]. N Engl J Med,2020, 383(24):2320-2332. DOI:10.1056/NEJMoa2026920.
[27]Salvatori G, Luberto L, Maffei M, Aurisicchio L,Roscilli G,Palombo F,Marra E. SARS-CoV-2 SPIKE PROTEIN:an optimal immunological target for vaccines[J/OL]. J Transl Med,2020,18(1):222.DOI:10.1186/s12967-020-02392-y.
[28]Guebre-Xabier M, Patel N, Tian J H, Zhou B,Maciejewski S,Lam K,Portnoff A D,Massare M J,Frieman M B,Piedra P A,Ellingsworth L,Glenn G,Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2challenge[J/OL]. Vaccine,2020,38(50):7892-7896.DOI:10.1016/j.vaccine.2020.10.064.
[29]Richmond P,Hatchuel L,Dong M,Ma B,Hu B,Smolenov I, Li P, Liang P, Han H H, Liang J,Clemens R. Safety and immunogenicity of S-Trimer(SCB-2019),a protein subunit vaccine candidate for COVID-19 in healthy adults:a phase 1,randomised,double-blind, placebo-controlled trial[J/OL]. The Lancet,2021,397(10275):682-694. DOI:10.1016/S0140-6736(21)00241-5.
[30]Xu R,Shi M,Li J,Song P,Li N. Construction of SARS-CoV-2 virus-like particles by mammalian expression system[J/OL]. Front Bioeng Biotechnol,2020,8:862. DOI:10.3389/fbioe.2020.00862.
[31]Mohsen M O,Balke I,Zinkhan S,Zeltina V,Liu X,Chang X,Krenger P S,Plattner K,Gharailoo Z,Vogt A S,Augusto G,Zwicker M,Roongta S,Rothen D A,Josi R,Costa J J D,Sobczak J M,Nonic A,Brand L A,Nuss K,Martina B,Speiser D E,Kündig T,Jennings G T,Walton S M,Vogel M,Zeltins A,Bachmann M F. A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2[J/OL]. Allergy,2022,77(1):243-257. DOI:10.1111/all.15080.
[32]Hennrich A A,Sawatsky B,Santos-Mandujano R,Banda D H,Oberhuber M,Schopf A,Pfaffinger V,Wittwer K,Riedel C,Pfaller C K,Conzelmann K K.Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19:Protection of mice after a single immunization[J/OL]. PLoS Pathog,2021, 17(4):e1009064. DOI:10.1371/journal.ppat.1009064.
[33]Xia J,Lu G,Lu J,Z J,Feng L,Wang B,Yu H,Xu Y,Lin J. Towards an effective mRNA vaccine against2019-nCoV:demonstration of virus-like particles expressed from a modified mRNA cocktail[J/OL].ChinaXiv,2020. DOI:10.12074/202002.00070.
[34]World Health Organization. Tracking SARS-CoV-2variants[EB/OL].[2021-12-14]. http://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
[35]Aleem A,A B A S,Slenker A K. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus(COVID-19)[B]. In:StatPearls[Internet]. Treasure Island(FL):StatPearls Publishing,2022.
[36]Zhang X,Wu S,Wu B,Yang Q,Chen A,Li Y,Zhang Y,Pan T,Zhang H,He X. SARS-CoV-2Omicron strain exhibits potent capabilities for immune evasion and viral entrance[J/OL]. Signal Transduct Target Ther,2021,6(1):1-3. DOI:10.1038/s41392-021-00852-5.
[37]Puranik A,Lenehan P J,Silvert E,Niesen M J M,Corchado-Garcia J,O'Horo J C,Virk A,Swift M D,Halamka J, Badley A D, Venkatakrishnan A J,Soundararajan V. Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence[J/OL]. medRxiv,2021.DOI:10.1101/2021.08.06.21261707.
[38]Heath P T, Galiza E P, Baxter D N, Boffito M,Browne D, Burns F, Chadwick D R, Clark R,Cosgrove C,Galloway J,Goodman A L,Heer A,Higham A,Iyengar S,Jamal A,Jeanes C,Kalra P A,Kyriakidou C,McAuley D F,Meyrick A,Minassian A M, Minton J, Moore P, Munsoor I, Nicholls H,Osanlou O,Packham J,Pretswell C H,San Francisco Ramos A,Saralaya D,Sheridan R P,Smith R,Soiza R L,Swift P A,Thomson E C,Turner J,Viljoen M E,Albert G,Cho I,Dubovsky F,Glenn G,Rivers J,Robertson A,Smith K,Toback S;2019nCoV-302GroupStudy. Safety and efficacy of NVX-CoV2373COVID-19 vaccine[J/OL]. N Engl J Med,2021,385(13):1172-1183. DOI:10.1056/NEJMoa2107659.
[39]Brinkkemper M, Brouwer P J M, Maisonnasse P,Grobben M,Caniels T G,Poniman M,Burger J A,Bontjer I,Oomen M,Bouhuijs J H,van der Linden C A,Villaudy J,van der Velden Y U,Sliepen K,van Gils M J,Le Grand R,Sanders R W. A third SARSCoV-2 spike vaccination improves neutralization of variants-of-concern[J/OL]. NPJ Vaccines,2021,6(1):146. DOI:10.1038/s41541-021-00411-7.
[40]Emary K R W,Golubchik T,Aley P K, Ariani C V,Angus B,Bibi S,Blane B,Bonsall D,Cicconi P,Charlton S,Clutterbuck E A,Collins A M,Cox T,Darton T C,Dold C,Douglas A D,Duncan C J A,Ewer K J,Flaxman A L,Faust S N,Ferreira D M,Feng S,Finn A,Folegatti P M,Fuskova M,Galiza E,Goodman A L,Green C M,Green C A,Greenland M,Hallis B,Heath P T,Hay J,Hill H C,Jenkin D,Kerridge S,Lazarus R,Libri V,Lillie P J,Ludden C,Marchevsky N G,Minassian A M,McGregor A C,Mujadidi Y F,Phillips D J,Plested E,Pollock K M,Robinson H, Smith A, Song R, Snape M D,Sutherland R K,Thomson E C,Toshner M,Turner D P J,Vekemans J,Villafana T L,Williams C J,Hill A V S,Lambe T,Gilbert S C,Voysey M,Ramasamy M N,Pollard A J;COVID-19 Genomics UK consortium;AMPHEUS Project;Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19(AZD1222)vaccine against SARS-CoV-2 variant of concern 202012/01(B. 1.1. 7):an exploratory analysis of a randomised controlled trial[J/OL]. Lancet,2021,397(10282):1351-1362. DOI:10.1016/S0140-6736(21)00628-0.
[41]Kustin T,Harel N,Finkel U,Perchik S,Harari S,Tahor M,Caspi I,Levy R,Leshchinsky M,Ken Dror S,Bergerzon G,Gadban H,Gadban F,Eliassian E,Shimron O,Saleh L,Ben-Zvi H,Keren Taraday E,Amichay D,Ben-Dor A,Sagas D,Strauss M,Shemer Avni Y,Huppert A,Kepten E,Balicer R D,Netzer D,Ben-Shachar S,Stern A. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals[J/OL].Nat Med,2021,27(8):1379-1384. DOI:10.1038/s41591-021-01413-7.
[42]Gómez C E, Perdiguero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19[J/OL].Vaccines(Basel),2021,9(3):243. DOI:10.3390/vaccines9030243.
[43]Starr T N, Greaney A J, Hilton S K, Ellis D,Crawford K H D,Dingens A S,Navarro M J,Bowen J E,Tortorici M A,Walls A C,King N P,Veesler D,Bloom J D. Deep mutational scanning of SARS-CoV-2receptor binding domain reveals constraints on folding and ACE2 binding[J/OL]. Cell,2020,182(5):1295-1310. DOI:10.1016/j.cell.2020.08.012.
[44]Jangra S, Ye C, Rathnasinghe R, Stadlbauer D,Krammer F,Simon V,Martinez-Sobrido L,GarciaSastre A,Schotsaert M. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and postvaccination sera[J/OL]. medRxiv,2021.DOI:10.1101/2021.01.26.21250543.
[45]Ranzani O T,Hitchings M D T,Dorion M,D'Agostini T L,de Paula R C,de Paula O F P,Villela E F M,Torres M S S,de Oliveira S B,Schulz W,Almiron M,Said R,de Oliveira R D,Vieira da Silva P,de Araújo W N,Gorinchteyn J C,Andrews J R,Cummings D A T,Ko A I,Croda J. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil:test negative case-control study[J/OL]. BMJ,2021,374:n2015. DOI:10.1136/bmj.n2091.
[46]Chung H,He S,Nasreen S,Sundaram M E,Buchan S A,Wilson S E,Chen B,Calzavara A,Fell D B,Austin P C,Wilson K,Schwartz K L,Brown K A,Gubbay J B,Basta N E,Mahmud S M,Righolt C H,Svenson L W,MacDonald S E,Janjua N Z,Tadrous M, Kwong J C; Canadian Immunization Research Network(CIRN)Provincial Collaborative Network(PCN)Investigators. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario,Canada:test negative design study[J/OL].BMJ,2021,374:n1943. DOI:10.1136/bmj.n1943.
[47]Sapkal G N,Yadav P D,Sahay R R,Deshpande G,Gupta N,Nyayanit D A,Patil D Y,Shete A M,Kumar S, Abraham P, Panda S, Bhargava B.Neutralization of Delta variant with sera of Covishield?vaccinees and COVID-19-recovered vaccinated individuals[J/OL]. J Travel Me,2021,28(7):taab119.DOI:10.1093/jtm/taab119.
[48]Jara A, Undurraga E A, González C, Paredes F,Fontecilla T,Jara G,Pizarro A,Acevedo J,Leo K,Leon F, Sans C, Leighton P, Suárez P, GarcíaEscorza H, Araos R. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile[J/OL]. N Engl J Med,2021, 385(10):875-884. DOI:10.1056/NEJMoa2107715.
[49]叶青.国产疫苗对德尔塔变异株有效吗?钟南山这样说[N].科技日报,2021. DOI:10.28502/n. cnki.nkjrb.2021.003499.
[50]Richmond P C, Hatchuel L, Pacciarini F, Hu B,Smolenov I, Li P, Liang P, Han H H, Liang J,Clemens R. Persistence of the immune responses and cross-neutralizing activity with variants of concern following 2 doses of adjuvanted SCB-2019 coronavirus disease 2019 vaccine[J/OL]. J Infect Dis,2021,224(10):1699-1706. DOI:10.1093/infdis/jiab447.
[51]Ambrosino D,Han H H,Hu B,Liang J,Clemens R,Johnson M,Siber G,Goldblatt D. Immunogenicity of SCB-2019 coronavirus disease 2019 vaccine compared with 4 approved vaccines[J/OL]. J Infect Dis,2022,225(2):327-331. DOI:10.1093/infdis/jiab574.
[52]Chen J,Wang R,Gilby N B,Wei G W. Omicron(B.1.1. 529):Infectivity, breakthroughvaccine, and antibody resistance[J/OL]. J Chem Inf Model,2022,62(2):412-422. DOI:10.1021/acs.jcim.1c01451.
[53]Cele S,Jackson L,Khan K,Khoury D,Moyo-Gwete T,Tegally H,Scheepers C,Amoako D,Karim F,Bernstein M,Lustig G,Archary D,Smith M,Ganga Y,Jule Z,Reedoy K,San J E,Hwa S H,Giandhari J,Blackburn J M,Gosnell B I,Karim S A,Hanekom W,NGS-SA,Team C K,von Gottberg A,Bhiman J,Lessells R J,Moosa M Y S,Davenport M,de Oliveira T,Moore P L,Sigal A. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2elicited neutralization and requires ACE2 for infection[J/OL].medRxiv, 2021.DOI:10.1101/2021.12.08.21267417.
[54]Wang Y,Zhang L,Li Q,Liang Z,Li T,Liu S,Cui Q,Nie J,Wu Q,Qu X,Huang W. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron[J/OL]. Emerg Microbes Infect,2022,11(1):1-5. DOI:10.1080/22221751.2021.2017757.
[55]Su S,Wang Q,Jiang S. Facing the challenge of viral mutations in the age of pandemic:Developing highly potent,broad-spectrum,and safe COVID-19 vaccines and therapeutics[J/OL]. Clin Transl Med,2021,11(1):e284. DOI:10.1002/ctm2.284.
[56]王李珏,刘泽众,姜世勃.新冠疫苗的有效性、安全性和广谱性的商榷[J/OL].中国科学基金,2020,34(05):588-593. DOI:10.16262/j. cnki. 1000-8217.20200914.001.
[57]Su S, Du L, Jiang S. Learning from the past:development of safe and effective COVID-19 vaccines[J/OL]. Nat Rev Microbiol,2021,19(3):211-219. DOI:10.1038/s41579-020-00462-y.
[58]Rosati M, Agarwal M, Hu X, Devasundaram S,Stellas D,Chowdhury B,Bear J,Burns R,Donohue D,Pessaint L,Andersen H,Lewis M G,Terpos E,Dimopoulos M A,Wlodawer A,Mullins J I,Venzon D J,Pavlakis G N,Felber B K. Control of SARS-CoV-2infection after Spike DNA or Spike DNA+Protein coimmunization in rhesus macaques[J/OL]. bioRxiv,2021. DOI:10.1371/journal.ppat.1009701.
[59]Rice A, Verma M, Shin A, Zakin L, Sieling P,Tanaka S,Balint J,Dinkins K,Adisetiyo H,Morimoto B,Higashide W,Anders Olson C,Mody S,Spilman P,Gabitzsch E,Safrit J T,Rabizadeh S,Niazi K,Soon-Shiong P. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice[J/OL]. Sci Rep,2021,11(1):1-15. DOI:10.1038/s41598-021-94364-5.
[60]Jangra S,Landers J J,Rathnasinghe R,O'Konek J J,Janczak K W,Cascalho M,Kennedy A A,Tai A W,Baker J R,Schotsaert M,Wong P T. A combination adjuvant for the induction of potent antiviral immune responses for a recombinant SARS-CoV-2 protein vaccine[J/OL]. Front Immunol, 2021, 12:729189.DOI:10.3389/fimmu.2021.729189.
[61]Liu Y,Dai L,Feng X,Gao R,Zhang N,Wang B,Han J,Zou Q,Guo X,Zhu H,Liu J,Qin C,Zhang Y,Bao L,Li M. Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA[J/OL]. Mol Biomed,2021,2(1):1-13. DOI:10.1186/s43556-021-00054-z.
基本信息:
DOI:10.13242/j.cnki.bingduxuebao.004121
中图分类号:R392-33
引用信息:
[1]季倩婷,尚浩天,施泽灿等.新型冠状病毒疫苗的研究策略及应对奥密克戎等变异株的挑战[J].病毒学报,2022,38(04):937-948.DOI:10.13242/j.cnki.bingduxuebao.004121.
基金信息:
浙大城市学院科研培育基金资助课题(项目号:J-202106),题目:SARS-CoV-2假病毒感染系统的建立及入侵抑制剂的研究~~
暂无数据